Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

InVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons Annual Meeting

InVivo Therapeutics Holdings Corp.
Posted on: 20 Sep 16

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Michael Fehlings, M.D., Ph.D., Director of the Spinal Program at the Krembil Neuroscience Centre of Toronto Western Hospital and a Professor of Neurosurgery at the University of Toronto, will give a late-breaking oral presentation titled “Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations from the INSPIRE Trial” at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract was one of the top three late-breaking abstracts chosen for an oral presentation.

“INSPIRE has provided new insights into acute spinal cord injury pathology, allowing for the application of the Neuro-Spinal ScaffoldTM as a potential new treatment modality for complete spinal cord injury. I’m looking forward to sharing the findings with the neurosurgical community,” Dr. Fehlings said.

Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said “We are delighted that important scientific observations being made in the INSPIRE study were selected for late-breaking oral presentation at a prestigious neurosurgical conference and that one of the leaders in the field of spinal cord injury treatment and research is making the presentation.”

As previously announced, Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation; Robert Heary, M.D., Director of the Spine Center at Rutgers New Jersey Medical School will be giving a poster presentation; and the company will have a steering committee meeting and exhibitor booth.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit

View source version on

Business Wire

Last updated on: 20/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.